Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., de Leval, L., Dirnhofer, S., et al. (2022) · Blood · doi:10.1182/blood.2022015851 · Cited by 1,608
Self-citationWright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M., Wang, J. Q., Schmitz, R., Morin, R. D., Tang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.015 · Cited by 1,169
Self-citationB Cell Responses: Cell Interaction Dynamics and Decisions
Cyster, J. G., & Allen, C. D. C. (2019) · Cell · doi:10.1016/j.cell.2019.03.016 · Cited by 971
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115304 · Cited by 926
Younes, A., Sehn, L. H., Johnson, P., Zinzani, P. L., Hong, X., Zhu, J., Patti, C., Belada, D., Samoilova, O., Suh, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02403 · Cited by 608
Self-citationNF‐κB signaling in inflammation and cancer
Zhang, T., Ma, C., Zhang, Z., Zhang, H., & Hu, H. (2021) · MedComm · doi:10.1002/mco2.104 · Cited by 574
Accurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
Lacy, S. E., Barrans, S. L., Beer, P. A., Painter, D., Smith, A. G., Roman, E., Cooke, S. L., Ruiz, C., Glover, P., Van Hoppe, S. J. L., et al. (2020) · Blood · doi:10.1182/blood.2019003535 · Cited by 506
Self-citationDiffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Bartlett, N. L., Wilson, W. H., Jung, S.-H., Hsi, E. D., Maurer, M. J., Pederson, L. D., Polley, M.-Y. C., Pitcher, B. N., Cheson, B. D., Kahl, B. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01994 · Cited by 434
Self-citationEnnishi, D., Jiang, A., Boyle, M., Collinge, B., Grande, B. M., Ben-Neriah, S., Rushton, C., Tang, J., Thomas, N., Slack, G. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01583 · Cited by 414
Self-citationA multiprotein supercomplex controlling oncogenic signalling in lymphoma
Phelan, J. D., Young, R. M., Webster, D. E., Roulland, S., Wright, G. W., Kasbekar, M., Shaffer, A. L., Ceribelli, M., Wang, J. Q., Schmitz, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0290-0 · Cited by 398
Self-citationSusanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Self-citationTargeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., Kurtz, D. M., Liu, C. L., Khameneh, F., Advani, R. H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.011 · Cited by 332
Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318
Self-citationEffect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wilson, W. H., Wright, G. W., Huang, D. W., Hodkinson, B., Balasubramanian, S., Fan, Y., Vermeulen, J., Shreeve, M., & Staudt, L. M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.006 · Cited by 315
Self-citationDistinction of lymphoid and myeloid clonal hematopoiesis
Niroula, A., Sekar, A., Murakami, M. A., Trinder, M., Agrawal, M., Wong, W. J., Bick, A. G., Uddin, M. M., Gibson, C. J., Griffin, G. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01521-4 · Cited by 307
Sha, C., Barrans, S., Cucco, F., Bentley, M. A., Care, M. A., Cummin, T., Kennedy, H., Thompson, J. S., Uddin, R., Worrillow, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01314 · Cited by 300
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Self-citationTranscriptional regulation of memory B cell differentiation
Laidlaw, B. J., & Cyster, J. G. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00446-2 · Cited by 296
Genetics of diffuse large B-cell lymphoma
Pasqualucci, L., & Dalla-Favera, R. (2018) · Blood · doi:10.1182/blood-2017-11-764332 · Cited by 282
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion
Dersh, D., Hollý, J., & Yewdell, J. W. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0390-6 · Cited by 278
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López-Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 278
Self-citationDavies, A., Cummin, T. E., Barrans, S., Maishman, T., Mamot, C., Novak, U., Caddy, J., Stanton, L., Kazmi-Stokes, S., McMillan, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30935-5 · Cited by 273
Epigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Kotlov, N., Bagaev, A., Revuelta, M. V., Phillip, J. M., Cacciapuoti, M. T., Antysheva, Z., Svekolkin, V., Tikhonova, E., Miheecheva, N., Kuzkina, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0839 · Cited by 267
Self-citationATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression
Tameire, F., Verginadis, I. I., Leli, N. M., Polte, C., Conn, C. S., Ojha, R., Salas Salinas, C., Chinga, F., Monroy, A. M., Fu, W., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0347-9 · Cited by 264
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Xiong, J., Cui, B.-W., Wang, N., Dai, Y.-T., Zhang, H., Wang, C.-F., Zhong, H.-J., Cheng, S., Ou-Yang, B.-S., Hu, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.005 · Cited by 233
Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J. W., Jagadeesh, D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30177-7 · Cited by 230
Self-citationHuang, Y.-H., Cai, K., Xu, P.-P., Wang, L., Huang, C.-X., Fang, Y., Cheng, S., Sun, X.-J., Liu, F., Huang, J.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00437-8 · Cited by 228
Inferring gene expression from cell-free DNA fragmentation profiles
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01222-4 · Cited by 221
Genetic alterations and their clinical implications in DLBCL
Miao, Y., Medeiros, L. J., Li, Y., Li, J., & Young, K. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0225-1 · Cited by 208
T follicular helper cells in germinal center B cell selection and lymphomagenesis
Mintz, M. A., & Cyster, J. G. (2020) · Immunological Reviews · doi:10.1111/imr.12860 · Cited by 204
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome
Holmes, A. B., Corinaldesi, C., Shen, Q., Kumar, R., Compagno, N., Wang, Z., Nitzan, M., Grunstein, E., Pasqualucci, L., Dalla-Favera, R., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200483 · Cited by 201
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL
Schmitt, A., Xu, W., Bucher, P., Grimm, M., Konantz, M., Horn, H., Zapukhlyak, M., Berning, P., Brändle, M., Jarboui, M.-A., et al. (2021) · Blood · doi:10.1182/blood.2020009404 · Cited by 193
Self-citationOllila, T. A., & Olszewski, A. J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0555-8 · Cited by 191
Cottereau, A.-S., Meignan, M., Nioche, C., Capobianco, N., Clerc, J., Chartier, L., Vercellino, L., Casasnovas, O., Thieblemont, C., & Buvat, I. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.019 · Cited by 189
The whole-genome landscape of Burkitt lymphoma subtypes
Panea, R. I., Love, C. L., Shingleton, J. R., Reddy, A., Bailey, J. A., Moormann, A. M., Otieno, J. A., Ong’echa, J. M., Oduor, C. I., Schroeder, K. M. S., et al. (2019) · Blood · doi:10.1182/blood.2019001880 · Cited by 186
Self-citationGerminal center‐derived lymphomas: The darkest side of humoral immunity
Mlynarczyk, C., Fontán, L., & Melnick, A. (2019) · Immunological Reviews · doi:10.1111/imr.12755 · Cited by 179
The genomic and transcriptional landscape of primary central nervous system lymphoma
Radke, J., Ishaque, N., Koll, R., Gu, Z., Schumann, E., Sieverling, L., Uhrig, S., Hübschmann, D., Toprak, U. H., López, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30050-y · Cited by 177
Self-citationMutational landscape of cancer-driver genes across human cancers
Sinkala, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-39608-2 · Cited by 176
Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Young, R. M., Phelan, J. D., Wilson, W. H., & Staudt, L. M. (2019) · Immunological Reviews · doi:10.1111/imr.12792 · Cited by 173
Self-citationNew agents and regimens for diffuse large B cell lymphoma
Wang, L., Li, L.-R., & Young, K. H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01011-z · Cited by 172
Genomic profiling for clinical decision making in lymphoid neoplasms
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 169
Self-citationRewiring cancer drivers to activate apoptosis
Gourisankar, S., Krokhotin, A., Ji, W., Liu, X., Chang, C.-Y., Kim, S. H., Li, Z., Wenderski, W., Simanauskaite, J. M., Yang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06348-2 · Cited by 169
Self-citationMeyer, S. N., Scuoppo, C., Vlasevska, S., Bal, É., Holmes, A. B., Holloman, M., Garcia‐Ibanez, L., Nataraj, S. E., Duval, R., Vantrimpont, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.006 · Cited by 169
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Kline, J., Godfrey, J., & Ansell, S. M. (2020) · Blood · doi:10.1182/blood.2019000847 · Cited by 167
Morschhauser, F., Feugier, P., Flinn, I. W., Gasiorowski, R., Greil, R., Illés, Á., Johnson, N. A., Larouche, J.-F., Lugtenburg, P. J., Patti, C., et al. (2021) · Blood · doi:10.1182/blood.2020006578 · Cited by 166
Self-citationMutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response
Béguelin, W., Teater, M., Meydan, C., Hoehn, K. B., Phillip, J. M., Soshnev, A. A., Venturutti, L., Rivas, M. A., Calvo-Fernández, M. T., Gutierrez, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.004 · Cited by 165
Shouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Afuye, A. O., Alperovich, A., Anagnostou, T., Besser, M. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02143 · Cited by 165
Kataoka, K., Miyoshi, H., Sakata, S., Dobashi, A., Couronné, L., Kogure, Y., Sato, Y., Nishida, K., Gion, Y., Shiraishi, Y., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0380-5 · Cited by 164
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 164
Rossi, D., Bertoni, F., & Zucca, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2102568 · Cited by 162
Mechanisms that regulate the activities of TET proteins
Joshi, K., Liu, S., Breslin S.J., P., & Zhang, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04396-x · Cited by 162
Primary vitreoretinal lymphoma: a diagnostic and management challenge
Soussain, C., Malaise, D., & Cassoux, N. (2021) · Blood · doi:10.1182/blood.2020008235 · Cited by 161
Advances in understanding of angioimmunoblastic T-cell lymphoma
Chiba, S., & Sakata-Yanagimoto, M. (2020) · Leukemia · doi:10.1038/s41375-020-0990-y · Cited by 161
Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
Lio, C. J., Yuita, H., & Rao, A. (2019) · Blood · doi:10.1182/blood.2019791475 · Cited by 161
Treatment strategies for patients with diffuse large B-cell lymphoma
Poletto, S., Novo, M., Paruzzo, L., Frascione, P. M. M., & Vitolo, U. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102443 · Cited by 159
Targeting the Bcl-2 Family in B Cell Lymphoma
Adams, C. M., Clark-Garvey, S., Porcu, P., & Eischen, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00636 · Cited by 159
Autio, M., Leivonen, S.-K., Brück, O., Mustjoki, S., Jørgensen, J. M., Karjalainen-Lindsberg, M.-L., Beiske, K., Holte, H., Pellinen, T., & Leppä, S. (2020) · Haematologica · doi:10.3324/haematol.2019.243626 · Cited by 159
TET Enzymes and 5hmC in Adaptive and Innate Immune Systems
Lio, C. J., & Rao, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00210 · Cited by 158
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 158
Anastasiadou, E., Seto, A. G., Beatty, X., Hermreck, M., Gilles, M.-E., Stroopinsky, D., Pinter-Brown, L. C., Pestano, L., Marchese, C., Avigan, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3139 · Cited by 157
Dersh, D., Phelan, J. D., Gumina, M. E., Wang, B., Arbuckle, J. H., Hollý, J., Kishton, R. J., Markowitz, T. E., Seedhom, M. O., Fridlyand, N., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.002 · Cited by 155
Self-citationFDG ‐ PET / CT in the management of lymphomas: current status and future directions
El‐Galaly, T. C., Villa, D. R., Gormsen, L. C., Bæch, J., Lo, A., & Cheah, C. Y. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12813 · Cited by 154
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 154
Management of relapsed/refractory DLBCL
Sarkozy, C., & Sehn, L. H. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.07.014 · Cited by 153
Feng, Y., Zhong, M., Zeng, S., Wang, L., Liu, P., Xiao, X., & Liu, Y. (2018) · Epigenomics · doi:10.2217/epi-2018-0123 · Cited by 151
Treatment resistance in diffuse large B-cell lymphoma
He, M. Y., & Kridel, R. (2021) · Leukemia · doi:10.1038/s41375-021-01285-3 · Cited by 149
Silkenstedt, E., Salles, G. A., Campo, E., & Dreyling, M. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02705-8 · Cited by 149
Self-citationHammood, M., Craig, A. W., & Leyton, J. V. (2021) · Pharmaceuticals · doi:10.3390/ph14070674 · Cited by 148
Zhang, M., Tian, S., Fu, D., Wang, L., Cheng, S., Yi, H., Jiang, X., Song, Q., Zhao, Y., He, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.004 · Cited by 148
Self-citationSuper-enhancer hypermutation alters oncogene expression in B cell lymphoma
Bal, E., Kumar, R., Hadigol, M., Holmes, A. B., Hilton, L. K., Loh, J. W., Dreval, K., Wong, J. C. H., Vlasevska, S., Corinaldesi, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04906-8 · Cited by 146
A Machine Learning Model for Accurate Prediction of Sepsis in ICU Patients
Wang, D., Li, J., Sun, Y., Ding, X., Zhang, X., Liu, S., Han, B., Wang, H., Duan, X., & Sun, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.754348 · Cited by 145
Meriranta, L., Alkodsi, A., Pasanen, A., Lepistö, M., Mapar, P., Blaker, Y. N., Jørgensen, J. M., Karjalainen‐Lindsberg, M., Fiskvik, I., Mikalsen, L. T. G., et al. (2021) · Blood · doi:10.1182/blood.2021012852 · Cited by 145
Mottok, A., Hung, S. S., Chavez, E. A., Woolcock, B. W., Telenius, A., Chong, L. C., Meissner, B., Nakamura, H., Rushton, C. K., Viganò, E., et al. (2019) · Blood · doi:10.1182/blood.2019001126 · Cited by 138
Self-citationGandhi, M. K., Hoang, T., Law, S. C., Brosda, S., O’Rourke, K., Tobin, J. W. D., Vari, F., Murigneux, V., Fink, J. L., Gunawardana, J., et al. (2020) · Blood · doi:10.1182/blood.2020008520 · Cited by 136
Self-citationShi, Y., Han, Y., Yang, J., Liu, P., He, X., Zhang, C., Zhou, S., Zhou, L., Qin, Y., Song, Y.-W., et al. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.01.10 · Cited by 131
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
Alig, S., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., et al. (2023) · Nature · doi:10.1038/s41586-023-06903-x · Cited by 132
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Rushton, C. K., Arthur, S. E., Alcaide, M., Cheung, M. C., Jiang, A., Coyle, K. M., Cleary, K. L. S., Thomas, N., Hilton, L. K., Michaud, N. R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001696 · Cited by 131
Self-citationSimplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
Shen, R., Fu, D., Dong, L., Zhang, M., Shi, Q., Shi, Z., Cheng, S., Wang, L., Xu, P., & Zhao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01358-y · Cited by 130
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma
Ramis-Zaldivar, J. E., González‐Farré, B., Balagué, O., Celis, V., Nadeu, F., Salmerón‐Villalobos, J., Andrés, M., Martín‐Guerrero, I., Garrido‐Pontnou, M., Gaafar, A., et al. (2019) · Blood · doi:10.1182/blood.2019002699 · Cited by 129
Self-citationTBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate
Venturutti, L., Teater, M., Zhai, A., Chadburn, A., Babiker, L., Kim, D., Béguelin, W., Lee, T. C., Kim, Y., Chin, C. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.049 · Cited by 127
“Mutations affecting TBL1XR1 associate with activating mutations in the BCR and TLR pathways (Chapuy et al., 2018; Schmitz et al., 2018), to define a group of aggressive extranodal post-GC lymphomas.”
InfluentialSelf-citationGodfrey, J. K., Tumuluru, S., Bao, R., Leukam, M. J., Venkataraman, G., Phillip, J., Fitzpatrick, C. A., McElherne, J., MacNabb, B. W., Orlowski, R. J., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879015 · Cited by 127
Cucco, F., Barrans, S., Sha, C., Clipson, A., Crouch, S., Dobson, R. C., Chen, Z., Thompson, J. S., Care, M. A., Cummin, T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0691-6 · Cited by 126
Hu, S., Ren, S., Cai, Y., Liu, J., Han, Y., Zhao, Y., Yang, J., Zhou, X., & Wang, X. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00880-2 · Cited by 126
Self-citationWang, L., Aschenbrenner, D., Zeng, Z., Cao, X., Mayr, D., Mehta, M., Capitani, M., Warner, N. E., Pan, J., Wang, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00803-4 · Cited by 125
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma
Dheilly, E., Battistello, E., Katanayeva, N., Sungalee, S., Michaux, J., Duns, G., Wehrle, S., Sordet‐Dessimoz, J., Mina, M., Racle, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.016 · Cited by 123
Nowakowski, G. S., Hong, F., Scott, D. W., Macon, W. R., King, R. L., Habermann, T. M., Wagner‐Johnston, N. D., Casulo, C., Wade, J. L., Nagargoje, G. G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01375 · Cited by 123
Self-citationA single-cell atlas of diffuse large B cell lymphoma
Ye, X., Wang, L., Nie, M., Wang, Y., Dong, S., Ren, W., Li, G., Li, Z., Wu, K., & Pan‐Hammarström, Q. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110713 · Cited by 123
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?
Morin, R. D., Arthur, S. E., & Hodson, D. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17811 · Cited by 121
Self-citationGenetic and epigenetic determinants of diffuse large B-cell lymphoma
Bakhshi, T. J., & Georgel, P. T. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00389-w · Cited by 120
Mutational landscape of gray zone lymphoma
Sarkozy, C., Hung, S. S., Chavez, E. A., Duns, G., Takata, K., Chong, L. C., Aoki, T., Jiang, A., Miyata‐Takata, T., Telenius, A., et al. (2020) · Blood · doi:10.1182/blood.2020007507 · Cited by 116
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome
Duran-Ferrer, M., Clot, G., Nadeu, F., Beekman, R., Baumann, T., Nordlund, J., Marincevic-Zuniga, Y., Lönnerholm, G., Rivas-Delgado, A., Martín, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00131-2 · Cited by 100
Self-citationGenetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma
Fangazio, M., Ladewig, E., Gomez, K., Garcia‐Ibanez, L., Kumar, R., Teruya‐Feldstein, J., Rossi, D., Filip, I., Pan‐Hammarström, Q., Inghirami, G. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104504118 · Cited by 114
Self-citationMolecular and clinical diversity in primary central nervous system lymphoma
Hernández-Verdín, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.002 · Cited by 113
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Lue, J. K., & Amengual, J. E. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0466-6 · Cited by 112
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Li, B., & Chng, W. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0814-6 · Cited by 112
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.